Riku Ota

Riku Ota is a skilled professional in health economics and outcomes research, currently serving as the Global Payer Evidence Lead at Novo Nordisk since May 2022. In this role, Riku is responsible for global payer strategy and evidence generation in liver-related pipelines, while also ensuring health technology assessment (HTA) functional excellence. Prior experience includes serving as an HEOR Manager at Novo Nordisk Japan, managing projects to secure patient access and sustain product value. Riku is actively involved in the international health economics community as the Chair of the New Professional Steering Committee for ISPOR and as a member of the EFPIA Access Committee HTA taskforce. Educational qualifications include an MBA from IE Business School (2025), an MPH from King's College London (2022), and advanced training in HTA from the University of Tokyo. Riku's background also includes experience in risk advisory at Deloitte and clinical research at LEO Pharma.